Samrotamab, also known as LCL100, represents a significant step in cancer research. This novel clonal protein is currently in clinical trials and demonstrates encouraging potential for treating multiple cancers, https://iwantpzu522292.aboutyoublog.com/51853866/samrotamab-a-potential-targeted-protein-in-development